These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22681312)

  • 1. Graft-versus-host disease reduces regulatory T-cell migration into the tumour tissue.
    Dürr C; Follo M; Idzko M; Reichardt W; Zeiser R
    Immunology; 2012 Sep; 137(1):80-8. PubMed ID: 22681312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
    Dürr C; Pfeifer D; Claus R; Schmitt-Graeff A; Gerlach UV; Graeser R; Krüger S; Gerbitz A; Negrin RS; Finke J; Zeiser R
    Cancer Res; 2010 Dec; 70(24):10170-81. PubMed ID: 21159639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells during Graft-versus-Host Disease.
    Klämbt V; Wohlfeil SA; Schwab L; Hülsdünker J; Ayata K; Apostolova P; Schmitt-Graeff A; Dierbach H; Prinz G; Follo M; Prinz M; Idzko M; Zeiser R
    J Immunol; 2015 Dec; 195(12):5795-804. PubMed ID: 26538394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.
    Nishikii H; Kim BS; Yokoyama Y; Chen Y; Baker J; Pierini A; Alvarez M; Mavers M; Maas-Bauer K; Pan Y; Chiba S; Negrin RS
    Blood; 2016 Dec; 128(24):2846-2858. PubMed ID: 27760760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
    Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
    Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
    Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
    Ranjan S; Goihl A; Kohli S; Gadi I; Pierau M; Shahzad K; Gupta D; Bock F; Wang H; Shaikh H; Kähne T; Reinhold D; Bank U; Zenclussen AC; Niemz J; Schnöder TM; Brunner-Weinzierl M; Fischer T; Kalinski T; Schraven B; Luft T; Huehn J; Naumann M; Heidel FH; Isermann B
    Nat Commun; 2017 Aug; 8(1):311. PubMed ID: 28827518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
    Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
    Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloantigen-specific regulatory T cells prevent experimental chronic graft-versus-host disease by simultaneous control of allo- and autoreactivity.
    Sagoo P; Ratnasothy K; Tsang Y; Barber LD; Noble A; Lechler RI; Lombardi G
    Eur J Immunol; 2012 Dec; 42(12):3322-33. PubMed ID: 22996319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
    Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
    Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg.
    Yu M; Wang J; Fang Q; Liu P; Chen S; Zhe N; Lin X; Zhang Y; Zhao J; Zhou Z
    Transpl Immunol; 2016 Jul; 37():10-17. PubMed ID: 27168057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of cyclic nucleotide phosphodiesterases in modulating T cell responses in murine graft-versus-host disease.
    Weber M; Lupp C; Stein P; Kreft A; Bopp T; Wehler TC; Schmitt E; Schild H; Radsak MP
    PLoS One; 2013; 8(3):e58110. PubMed ID: 23483980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.